Malcova develops advanced medical imaging technology, including patented Narrow-Beam CT, for early and accurate disease detection. This technology provides highly detailed diagnostic clarity with lower radiation doses and greater patient comfort than traditional methods. The company offers tools like Digital Twins and an AI-based Diagnostic Agent to support radiologists in achieving superior diagnostic precision.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NSFounders
Product
Problem
Current breast cancer imaging technologies may not be equally effective for all women due to variations in breast density and individual patient characteristics. This can lead to missed diagnoses or the need for additional, potentially invasive, procedures. There is a need for more personalized and accurate breast cancer detection methods.
Solution
MALCOVA is developing medical devices and AI-driven software to improve breast cancer imaging and provide personalized healthcare solutions for women. Their approach focuses on creating technologies that are effective for a diverse range of patients and clinicians. By collaborating with medical institutions and research universities, MALCOVA aims to enhance diagnostic accuracy and tailor breast cancer detection methods to individual needs.
Target Audience
The primary target audience includes clinicians specializing in breast cancer imaging and women seeking more effective and personalized breast cancer screening and diagnostic tools.
Features
- AI-driven software for enhanced image analysis
- Collaboration with medical institutions for clinical validation
- Focus on personalized healthcare solutions for women
- Development of medical devices for breast cancer imaging